IOL Chemicals And Pharmaceuticals Share Price
202.91+0.00 (-0.12%)
+69.19% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
LUPINNSE
IOLCPNSE
IOL Chemicals And Pharmaceuticals Share Price
202.91+0.00 (-0.12%)
+69.19% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | - | 2% | 12% |
| - | - | 0% | 36% |
| 21% | 12% | 28% | 69% |
| 9% | 9% | 8% | 8% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
MANKIND
DRREDDY
AUROPHARMA
LUPIN
IOLCP
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,846.4 | ₹448196 Cr | 37.05 | 12.07 | 62.82 | ₹11479 Cr |
| 9,352 | ₹250390 Cr | 85.6 | 34.04 | 128.41 | ₹2568 Cr |
| 4,935 | ₹188967 Cr | 86.64 | 16.72 | 97.06 | ₹2163 Cr |
| 1,162.3 | ₹115860 Cr | 25.67 | 9.42 | 62.53 | ₹5040 Cr |
| 1,384.1 | ₹111888 Cr | 33.19 | 9.77 | 57.87 | ₹3879 Cr |
| 2,006.5 | ₹109035 Cr | 99.72 | 6.8 | 29.25 | ₹889 Cr |
| 2,480 | ₹100364 Cr | 49.13 | 13.75 | 71.08 | ₹1913 Cr |
| 1,211 | ₹100329 Cr | 31.14 | 5.32 | 63.99 | ₹4196 Cr |
| 1,700 | ₹98804 Cr | 26.61 | 17.95 | 96.84 | ₹3505 Cr |
| 2,135 | ₹96940 Cr | 17.53 | 30.95 | 154.36 | ₹5333 Cr |
| 200.39 | ₹5963 Cr | 35.47 | 2.19 | 8.51 | ₹138 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹756 Cr | ₹619 Cr | ₹580 Cr | ₹568 Cr | ₹552 Cr | ₹528 Cr | ₹523 Cr | ₹526 Cr | ₹502 Cr | ₹504 Cr | ₹520 Cr | ₹545 Cr | ₹563 Cr | ₹587 Cr | ₹523 Cr | ₹541 Cr | ₹565 Cr | ₹572 Cr |
| ₹8 Cr | ₹2 Cr | ₹5 Cr | ₹7 Cr | ₹7 Cr | ₹5 Cr | ₹4 Cr | ₹6 Cr | ₹7 Cr | ₹8 Cr | ₹8 Cr | ₹7 Cr | ₹7 Cr | ₹9 Cr | ₹7 Cr | ₹5 Cr | ₹5 Cr | ₹7 Cr |
| ₹764 Cr | ₹621 Cr | ₹586 Cr | ₹574 Cr | ₹559 Cr | ₹532 Cr | ₹527 Cr | ₹532 Cr | ₹510 Cr | ₹511 Cr | ₹529 Cr | ₹552 Cr | ₹570 Cr | ₹596 Cr | ₹530 Cr | ₹546 Cr | ₹570 Cr | ₹579 Cr |
| ₹674 Cr | ₹547 Cr | ₹543 Cr | ₹530 Cr | ₹509 Cr | ₹484 Cr | ₹495 Cr | ₹502 Cr | ₹468 Cr | ₹471 Cr | ₹492 Cr | ₹497 Cr | ₹505 Cr | ₹504 Cr | ₹493 Cr | ₹521 Cr | ₹520 Cr | ₹538 Cr |
| ₹112 Cr | ₹94 Cr | ₹63 Cr | ₹64 Cr | ₹70 Cr | ₹67 Cr | ₹51 Cr | ₹48 Cr | ₹58 Cr | ₹57 Cr | ₹53 Cr | ₹71 Cr | ₹80 Cr | ₹104 Cr | ₹49 Cr | ₹37 Cr | ₹61 Cr | ₹52 Cr |
| ₹4 Cr | ₹3 Cr | ₹4 Cr | ₹3 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹2 Cr | ₹3 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹5 Cr | ₹5 Cr | ₹4 Cr | ₹3 Cr | ₹2 Cr |
| ₹87 Cr | ₹71 Cr | ₹28 Cr | ₹40 Cr | ₹46 Cr | ₹45 Cr | ₹28 Cr | ₹26 Cr | ₹40 Cr | ₹37 Cr | ₹32 Cr | ₹51 Cr | ₹61 Cr | ₹87 Cr | ₹33 Cr | ₹22 Cr | ₹47 Cr | ₹39 Cr |
| ₹64 Cr | ₹53 Cr | ₹21 Cr | ₹30 Cr | ₹34 Cr | ₹31 Cr | ₹21 Cr | ₹19 Cr | ₹30 Cr | ₹28 Cr | ₹23 Cr | ₹38 Cr | ₹46 Cr | ₹65 Cr | ₹24 Cr | ₹16 Cr | ₹35 Cr | ₹30 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| — | — | — | — | — |
| ₹59 Cr | ₹59 Cr | ₹59 Cr | ₹59 Cr | ₹59 Cr |
| ₹1740 Cr | ₹1629 Cr | ₹1553 Cr | ₹1449 Cr | ₹1334 Cr |
| ₹1740 Cr | ₹1629 Cr | ₹1553 Cr | ₹1449 Cr | ₹1334 Cr |
| ₹1799 Cr | ₹1688 Cr | ₹1612 Cr | ₹1508 Cr | ₹1392 Cr |
| ₹85 Cr | ₹78 Cr | ₹66 Cr | ₹56 Cr | ₹53 Cr |
| ₹2 Cr | ₹0 | ₹4 L | ₹14 L | ₹43 L |
| ₹11 Cr | ₹7 Cr | ₹7 Cr | ₹2 Cr | ₹3 Cr |
| ₹98 Cr | ₹85 Cr | ₹73 Cr | ₹58 Cr | ₹57 Cr |
| — | — | — | — | — |
| ₹483 Cr | ₹428 Cr | ₹469 Cr | ₹314 Cr | ₹409 Cr |
| ₹70 Cr | ₹63 Cr | ₹55 Cr | ₹54 Cr | ₹54 Cr |
| ₹132 Cr | ₹117 Cr | ₹33 Cr | ₹80 Cr | ₹43 Cr |
| ₹49 Cr | ₹31 Cr | ₹40 Cr | ₹54 Cr | ₹69 Cr |
| ₹733 Cr | ₹639 Cr | ₹597 Cr | ₹503 Cr | ₹575 Cr |
| ₹2630 Cr | ₹2411 Cr | ₹2282 Cr | ₹2068 Cr | ₹2024 Cr |
| ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹5 Cr | ₹18 L |
| ₹132 Cr | ₹117 Cr | ₹33 Cr | ₹80 Cr | ₹43 Cr |
| — | — | — | — | — |
| ₹1632 Cr | ₹1544 Cr | ₹1236 Cr | ₹995 Cr | ₹762 Cr |
| ₹451 Cr | ₹374 Cr | ₹303 Cr | ₹243 Cr | ₹201 Cr |
| ₹1182 Cr | ₹1171 Cr | ₹933 Cr | ₹752 Cr | ₹561 Cr |
| ₹94 Cr | ₹21 Cr | ₹100 Cr | ₹81 Cr | ₹102 Cr |
| ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹0 |
| ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹0 |
| ₹20 Cr | ₹12 Cr | ₹24 Cr | ₹10 Cr | ₹11 Cr |
| ₹45 Cr | ₹9 Cr | ₹50 Cr | ₹233 Cr | ₹205 Cr |
| ₹1359 Cr | ₹1231 Cr | ₹1125 Cr | ₹1102 Cr | ₹881 Cr |
| — | — | — | — | — |
| ₹4 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹2 Cr |
| ₹371 Cr | ₹361 Cr | ₹425 Cr | ₹326 Cr | ₹410 Cr |
| ₹603 Cr | ₹514 Cr | ₹471 Cr | ₹505 Cr | ₹470 Cr |
| ₹198 Cr | ₹208 Cr | ₹143 Cr | ₹22 Cr | ₹140 Cr |
| ₹30 Cr | ₹27 Cr | ₹25 Cr | ₹30 Cr | ₹31 Cr |
| ₹65 Cr | ₹67 Cr | ₹90 Cr | ₹82 Cr | ₹90 Cr |
| ₹1271 Cr | ₹1180 Cr | ₹1157 Cr | ₹967 Cr | ₹1143 Cr |
| ₹537 Cr | ₹541 Cr | ₹560 Cr | ₹464 Cr | ₹567 Cr |
| ₹2630 Cr | ₹2411 Cr | ₹2282 Cr | ₹2068 Cr | ₹2024 Cr |
| ₹61 | ₹57 | ₹274 | ₹257 | ₹237 |
| ₹61 | ₹57 | ₹55 | ₹257 | ₹237 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| ₹184 Cr | ₹138 Cr | ₹182 Cr | ₹189 Cr | ₹225 Cr |
| ₹85 Cr | ₹80 Cr | ₹60 Cr | ₹44 Cr | ₹33 Cr |
| -₹17 Cr | -₹21 Cr | ₹90 Cr | -₹64 Cr | -₹102 Cr |
| ₹252 Cr | ₹197 Cr | ₹332 Cr | ₹169 Cr | ₹156 Cr |
| ₹214 Cr | ₹179 Cr | ₹290 Cr | ₹122 Cr | ₹93 Cr |
| -₹198 Cr | -₹154 Cr | -₹191 Cr | -₹120 Cr | -₹121 Cr |
| -₹29 Cr | ₹46 Cr | -₹93 Cr | -₹4 Cr | -₹2 Cr |
| -₹13 Cr | ₹70 Cr | ₹6 Cr | -₹2 Cr | -₹29 Cr |
| ₹78 Cr | ₹8 Cr | ₹1 Cr | ₹3 Cr | ₹32 Cr |
| ₹65 Cr | ₹78 Cr | ₹8 Cr | ₹1 Cr | ₹3 Cr |
Fundamental Ratios
Consolidated
Standalone
No results found
IOL Chemicals And Pharmaceuticals Share Price
202.91+0.00 (-0.12%)
+69.19% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 4
Bearish signals: 2 out of 9 oscillators
RSI
59.66Buy
STOCH %K
64.54Neutral
MACD Level(12,26)
8.49Buy
Ultimate Oscillator
47.64Sell
Aroon Oscillator
54.00Buy
BOP
-0.03Sell
CCI
66.31Neutral
Williams %R
-35.46Neutral
Momentum
9.22Buy
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 9
Bearish signals: 0 out of 9 moving averages
EMA 9
198.73Buy
SMA 9
200.41Buy
EMA 21
192.08Buy
SMA 21
193.84Buy
EMA 50
175.48Buy
SMA 50
172.78Buy
EMA 200
129.72Buy
SMA 200
114.03Buy
WMA 20
198.63Buy
Pivot
Pivot
Classic
Resistance 5
242.82
Resistance 4
232.52
Resistance 3
222.22
Resistance 2
211.92
Resistance 1
207.53
Pivot
201.62
Support 1
197.23
Support 2
191.32
Support 3
181.02
Support 4
170.72
Support 5
160.42
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
IOL Chemicals And Pharmaceuticals Share Price
202.91+0.00 (-0.12%)
+69.19% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| 62.28% | 57.48% | 52.62% | 52.62% | 52.62% | 52.62% |
| 4.87% | 1.72% | 2.08% | 2.25% | 2.59% | 1.47% |
| 0.41% | 0.00% | 0.00% | 0.02% | 0.00% | 0.05% |
| 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% |
| 32.42% | 40.78% | 45.28% | 45.09% | 44.77% | 45.84% |
Bulk & block deals
Name
Microcurves Trading Private Limited
Qe Securities Llp
Hrti Private Limited
Hrti Private Limited
Microcurves Trading Private Limited
Qe Securities Llp
Polunin Emerging Markets Small Cap Fund Llc
Graviton Research Capital Llp
Qe Securities Llp
Musigma Securities
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 08 Jul 2026 | Purchase | 26.91 Cr | ₹170.97 | 15.74 L | Bulk | 0.536278 | NSE |
| 08 Jul 2026 | Purchase | 26.16 Cr | ₹168.77 | 15.50 L | Bulk | 0.528044 | NSE |
| 08 Jul 2026 | Purchase | 19.37 Cr | ₹168.72 | 11.48 L | Bulk | 0.391057 | NSE |
| 08 Jul 2026 | Sell | 36.67 Cr | ₹169.61 | 21.62 L | Bulk | 0.736555 | NSE |
| 08 Jul 2026 | Sell | 26.92 Cr | ₹171.04 | 15.74 L | Bulk | 0.536278 | NSE |
| 08 Jul 2026 | Sell | 25.83 Cr | ₹170.49 | 15.15 L | Bulk | 0.516173 | NSE |
| 07 Jul 2026 | Purchase | 73.65 Cr | ₹166.65 | 44.19 L | Bulk | 1.505556 | NSE |
| 09 Sep 2025 | Purchase | 63.49 Cr | ₹117.96 | 53.83 L | Bulk | 1.833774 | NSE |
| 09 Sep 2025 | Purchase | 23.28 Cr | ₹117.52 | 19.81 L | Bulk | 0.674902 | NSE |
| 09 Sep 2025 | Purchase | 22.63 Cr | ₹117.82 | 19.21 L | Bulk | 0.654485 | NSE |
Insider trading & SAST
Client name
Ncvi Enterprises Ltd & Pacs
Mayadevi Polycot Ltd & Pacs
Nm Merchantiles Ltd
Ncvi Enterprises Ltd & Pacs
Mayadevi Polycot Ltd & Pacs
Ncvi Enterprises Ltd & Pacs
Ncvi Enterprises Limited
Mayadevi Polycot Limited
Ncvi Enterprises Limited
Mayadevi Polycot Limited
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17 Apr 2026 | Promoter | Acquisition | 0.24 | 56.86 | 0 | — | 7 L | 16 Mar 2026 | Market | 16,69,04,180 | SAST | 29(2) | — |
| 17 Apr 2026 | Promoter | Acquisition | 0.02 | 57.1 | 0 | — | 54.20 K | 18 Mar 2026 | Market | 16,76,12,500 | SAST | 29(2) | — |
| 17 Apr 2026 | Promoter | Acquisition | 4 | 17.08 | 0 | — | 1.17 Cr | 05 Mar 2026 | Merger | 5,01,31,650 | SAST | 29(2) | — |
| 17 Apr 2026 | Promoter | Acquisition | 0.14 | 57.48 | 0 | — | 4.04 L | 19 Mar 2026 | Market | 16,87,16,805 | SAST | 29(2) | — |
| 17 Apr 2026 | Promoter | Acquisition | 0.22 | 57.08 | 0 | — | 6.54 L | 17 Mar 2026 | Market | 16,75,58,303 | SAST | 29(2) | — |
| 17 Apr 2026 | Promoter | Acquisition | 0.24 | 57.34 | 0 | — | 7 L | 18 Mar 2026 | Market | 16,83,12,500 | SAST | 29(2) | — |
| 20 Mar 2026 | Promoter Group | Acquisition | 0.13774 | 16.58 | 3.01 Cr | ₹74.56 | 4.04 L | 19 Mar 2026 | Market Purchase | 4,86,55,000 | Insider Trading | — | Equity Shares |
| 19 Mar 2026 | Promoter Group | Acquisition | 0.018464 | 21.78 | 40 L | ₹73.81 | 54.20 K | 18 Mar 2026 | Market Purchase | 6,39,45,330 | Insider Trading | — | Equity Shares |
| 19 Mar 2026 | Promoter Group | Acquisition | 0.238479 | 16.44 | 5.14 Cr | ₹73.44 | 7 L | 18 Mar 2026 | Market Purchase | 4,82,50,695 | Insider Trading | — | Equity Shares |
| 18 Mar 2026 | Promoter Group | Acquisition | 0.222849 | 21.76 | 4.47 Cr | ₹68.36 | 6.54 L | 17 Mar 2026 | Market Purchase | 6,38,91,133 | Insider Trading | — | Equity Shares |
IOL Chemicals And Pharmaceuticals Share Price
202.91+0.00 (-0.12%)
+69.19% past 1 Year
IOL Chemicals & Pharmaceuticals Ltd. was established in 1986 IOL Chemicals & Pharmaceuticals is India's one of the leading generic pharmaceutical company and is significant player in the Organic chemicals
Corporate Actions
Date
Type
Details
Company details
IOL Chemicals And Pharmaceuticals Share Price
202.91+0.00 (-0.12%)
+69.19% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
IOL Chemicals And Pharmaceuticals Share Price
202.91+0.00 (-0.12%)
+69.19% past 1 Year
News
IOL Chemicals plans new ibuprofen plant, expands total capacity in Punjab
Equity
IOLCP
IOL Chemicals And Pharmaceuticals schedules investor and analyst meet on September 3
Equity
IOLCP
IOL Chemicals reports Q1 revenue rises to Rs 760 crores year on year
Equity
IOLCP
IOL Chemicals reports higher Q1 EBITDA with margin expansion
Equity
IOLCP
IOL Chemicals reports stronger Q1 net profit on year
Equity
IOLCP
IOL Chemicals gets CHINA NMPA approval for Clopidogrel Bisulfate API export
Equity
IOLCP
IOL Chemicals temporarily halts Minoxidil plant operations after small fire incident
Equity
IOLCP
IOL Chem & Pharma - Quaterly Results
Equity
IOLCP
IOL Chem & Pharma reports Profit after tax of 53.18 Crores, in the March 2026 quarter
Equity
IOLCP
IOL Chemicals Q4 revenue rises year-on-year, indicating stronger topline performance
Equity
IOLCP
IOL Chemicals Q4 EBITDA jumps with improved operating margin performance YoY
Equity
IOLCP
IOL Chemicals Q4 standalone net profit jumps 68 percent year-on-year
Equity
IOLCP
IOL Chemicals & Pharmaceuticals informs about disclosure
Equity
IOLCP
IOL Chemicals & Pharmaceuticals informs about disclosure
Equity
IOLCP
IOL Chemicals & Pharmaceuticals informs about disclosure
Equity
IOLCP
IOL Chemicals and Pharmaceuticals Receives CEP Approval for Metformin Hydrochloride Process-II API from EDQM.
Equity
IOLCP
IOL Chemicals Enhances Ethyl Acetate Capacity to 120,000 MTpa and Acetic Anhydride to 32,000 MTpa with Rs 5.71 Crores Investment.
Equity
IOLCP
IOL Chemicals soars on getting Certificate of Suitability from EDQM
Equity
IOLCP
IOL Chemicals and Pharmaceuticals gets Certificate of Suitability from EDQM
Equity
IOLCP
IOL Chemicals Receives EDQM CEP for Clopidogrel Besilate API
Equity
IOLCP